(1R,2S)-2-(3,4-Difluorophenyl)cyclopropanamine (2R)-Hydroxy(phenyl)ethanoate

Product Overview: (1R,2S)-2-(3,4-Difluorophenyl)cyclopropanamine (2R)-Hydroxy(phenyl)ethanoate

Table of Contents

• Technical Specifications & Comparative Analysis
• Pharmaceutical Applications
• Quality Control Parameters
• Industrial Case Studies
• Procurement Guidance
• Supplier Inquiry

Technical Specifications & Comparative Analysis

This chiral cyclopropane derivative serves as critical intermediate in antithrombotic drug synthesis. Structural analogs differ in stereochemistry at positions 1R/2S versus 1S/2R configurations, significantly impacting biological activity. The (2R)-hydroxy(phenyl)ethanoate counterion enhances stability during API manufacturing compared to hydrochloride salts.

Pharmaceutical Applications

Primary application: Key intermediate for Ticagrelor (Brilinta®), a P2Y₁₂ platelet inhibitor. Required for constructing the cyclopropane-containing pharmacophore that enables irreversible binding to ADP receptors. Global demand driven by cardiovascular treatment markets, with annual consumption exceeding 8 metric tons.

Quality Control Parameters

Industrial Case Studies

Case 1: Jiangsu Pules Biotech (2024) achieved 92% yield improvement through asymmetric cyclopropanation optimization, reducing critical impurities to <0.1%.

Case 2: Wuhan Lihe Pharma’s continuous flow synthesis platform (2025 Q1) demonstrated 40% cost reduction while maintaining 99.5% chiral purity.

Procurement Guidance

1. Verify chiral purity certificates with CDMO’s analytical reports
2. Require ICH stability data (accelerated 40°C/75% RH)
3. Confirm regulatory support for DMF/CEP filings

Supplier Inquiry

Contact our technical team for current batch availability and custom synthesis options:

Email: info@vivalr.com
Tel: (86) 15866781826